Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18988077 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL18987481 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL18987483 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL23731054 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL18987387 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL23812909 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL18987385 | 1.00 | HPGDS (0.73) | HPGDS | |
| SCHEMBL23812903 | 0.90 | HPGDS (0.75) | HPGDS | |
| SCHEMBL19021496 | 0.90 | HPGDS (0.75) | HPGDS | |
| SCHEMBL18987565 | 0.90 | HPGDS (0.75) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | claimed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | claimed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3390384-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | Astex Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | HPGDS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.